LifeVantage reports fourth-quarter and fiscal 2026 revenue decline, skips 2027 guidance

LifeVantage Corporation reported financial results for the fourth quarter and full fiscal year 2026 on August 27, 2026. Revenue for the quarter ended June 30, 2026 was $42.4 million, a 23.1% decrease compared to $55.1 million in the same quarter of fiscal 2025.¹ The company attributed the decline mainly to fewer orders from its active account base and smaller average order sizes tied to the broader macroeconomic environment, along with lower sales of its MindBody GLP-1 System as it compared against a stronger prior-year quarter, partly offset by sales of LoveBiome, acquired in October 2025.¹

For the full fiscal year, revenue came to $182.6 million, a 20.1% decrease from $228.5 million in fiscal 2025.¹

The company said it will not provide formal guidance for the coming year. LifeVantage stated that due to the recent transition in the Chief Executive Officer role, it is not issuing formal guidance for fiscal 2027 at this time.¹ New CEO Terrence Moorehead said in the release that his early focus will be on strengthening the LifeVantage brand, building a more relevant consumer proposition, and driving operational excellence.¹

On liquidity, the company said it generated $10.2 million in cash from operations during fiscal 2026, versus $11.9 million in fiscal 2025, and closed the year with $14.9 million in cash and cash equivalents, down from $20.2 million a year earlier, with no debt outstanding.¹ During fiscal 2026 the company repurchased about 336,000 shares for roughly $2.0 million, leaving $58.5 million available under the $60 million buyback program its board approved in January.¹

LifeVantage will hold an investor call the same day to discuss the results, with a replay available through September 17, 2026.